全球研发|复星医药创新肿瘤免疫疗法FXB0871中国I期临床试验完成首例参与者给药

FXB0871（复星医药权益范围外药物名称为TEV-56278）是一款PD-1靶向型减弱IL-2融合蛋白免疫疗法（ATTENUKINETM），为一款全球前沿的创新药物。FXB0871旨在将减弱的IL-2选择性递送至PD-1阳性的T细胞，从而增强T细胞抗肿瘤活性，同时尽可能减少非靶向的系统性毒性。临床前研究数据显示，该药物可实现肿瘤消退、增强T细胞浸润并形成持久的免疫记忆。迄今为止，全球范围内尚无基于IL-2并可选择性靶向递送至肿瘤反应性 T 细胞的药品获批上市。

根据双方此前达成的协议，复星医药拥有该产品在中国及约定的东南亚国家的独家开发、生产和商业化权利，双方将共享临床数据，共同加速这一创新疗法的研发进展。目前，TEV-56278/FXB0871的国际多中心I期临床研究正在美国及加拿大开展。

作为一家创新驱动的全球化医药健康产业集团，复星医药已形成开放式、全球化的创新研发体系，围绕未满足临床需求，深度布局肿瘤、免疫炎症、神经退行性疾病等核心治疗领域，积极拓展慢病及罕见病等领域，打造具有长期竞争力的产品管线与综合解決方案。同时，复星医药持续夯实抗体和抗体偶联药物（ADC）、小分子、细胞治疗等核心技术平台，拓展核药、小核酸等前沿技术，强化早期创新能力，加速科研成果转化。

未来，复星医药将持续深耕创新研发赛道，依托成熟完善的本土临床开发体系与专业研发团队，有序推进后续临床试验进程。公司将以临床需求为导向，加速创新药物研发与成果转化，不断丰富肿瘤管线布局，力争早日为患者提供更优质、更可及的全新治疗选择。

* ATTENUKINE™ 是梯瓦制药工业有限公司的注册商标。

Fosun Pharma Announces First Participant Dosed in China Phase 1 Trial of FXB0871, an Innovative Immuno-oncology therapy

(29 May, 2026, Shanghai China) 29 May 2026，Fosun Pharma (600196.SH; 02196.HK) today announced that the first participant in Chinese Mainland was dosed for the Phase 1 clinical trial of FXB0871, an PD-1-Targeted Attenuated IL-2 Fusion Protein Immunotherapy (ATTENUKINE™ *) developed in collaboration with Teva Pharmaceutical Industries Ltd. (Teva, NYSE & TASE: TEVA). This marks a significant milestone in the clinical development of this investigational, innovative drug in China, laying a critical foundation for the subsequent exploration of differentiated immuno-oncology combination therapies.

FXB0871 (TEV-56278 outside of Fosun Pharma’s territory) is a PD-1-Targeted Attenuated IL-2 Fusion Protein Immunotherapy (ATTENUKINE™), which is a cutting-edge technology. FXB0871 is designed to selectively deliver attenuated IL-2 to PD-1-positive T cells, thereby potentially enhancing T-cell anti-tumor activity while minimizing off-target systemic toxicity. Preclinical research data have demonstrated that the drug induces tumor regression, increases T-cell infiltration, and generates durable immune memory. To date, no IL‑2–based product with targeted delivery selectively directed to tumor-reactive T cells has been approved for launch globally.

Pursuant to the existing agreement between the parties, Fosun Pharma is granted an exclusive license to develop, manufacture and commercialize TEV-56278 in Chinese mainland, Hong Kong SAR, Macau SAR and Taiwan region and select Southeast Asian countries. The parties will share clinical data to jointly accelerate the research and development of this novel therapy. Currently, the international Phase 1 clinical study of TEV-56278/FXB0871 is ongoing in the United States and Canada.

As an innovation-driven global pharmaceutical and healthcare group, Fosun Pharma has established an open-ended and global innovation R&D system. Targeting unmet clinical needs, the Group has a deep presence in core therapeutic areas such as oncology, immunology and inflammation, and neurodegenerative diseases, while actively expanding into chronic diseases and rare diseases to build a product pipeline and integrated solutions with long-term competitiveness. At the same time, Fosun Pharma continues to strengthen its core technology platforms including antibodies and antibody-drug conjugates (ADCs), small molecules, and cell therapy, while expanding into cutting-edge technologies such as radiopharmaceuticals and small nucleic acids, reinforcing its early-stage innovation capabilities and accelerating the transformation of scientific discoveries

Going forward, Fosun Pharma will continue to focus on innovative R&D tracks, leveraging its well-established local clinical development system and professional R&D team to advance subsequent clinical trials in an orderly manner. Guided by clinical needs, the Company will accelerate the R&D and transformation of innovative drugs, continuously enrich its oncology pipeline, and strive to bring new, high-quality, and accessible treatment options to patients as soon as possible.

*ATTENUKINE™ is a registered trademark of Teva Pharmaceutical Industries Ltd.

媒体：pr@fosunpharma.com

投资人：ir@fosunpharma.com